Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Yesterday, Sept. 4, 2013, 135 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $375.00 to $6,781,627.44. Highlighted Stocks Traded by Insiders: InterMune (ITMN) - FREE Research Report Kabakoff David S who is Director at InterMune sold 10,002 shares at $14.82 on Sept. 4, 2013. Following this transaction, the Director owned 30,500 shares meaning that the stake was reduced by 24.7% with the 10,002 share transaction. The shares most recently traded at $15.00, up $0.18, or 1.19% since the insider transaction. The average volume for InterMune has been 1.3 million shares per day over the past 30 days. InterMune has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 54.7% year to date as of the close of trading on Wednesday. InterMune, Inc., a biotechnology company, engages in the research, development, and commercialization of therapies in pulmonology and orphan fibrotic diseases. The company focuses on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Currently there are 10 analysts that rate InterMune a buy, 1 analyst rates it a sell, and 2 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on ITMN - FREETheStreet Quant Ratings rates InterMune as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full InterMune Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.